Travere Therapeutics: Eric Dube plans $6.3M sale

Travere Therapeutics, Inc. (TVTX) received a notice that Eric Dube plans to sell shares of the company’s common stock under Rule 144.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) received a notice that Eric Dube plans to sell shares of the company’s common stock under Rule 144. The notice covers up to 95,666 shares of common stock with an aggregate market value of $6,293,866.14 as of September 15, 2026.

The planned sale is to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ market and is tied to the exercise of stock options for cash on September 15, 2026.

Key Figures

Shares to be sold under Rule 144: 95,666 shares Aggregate market value: $6,293,866.14 Date of proposed sale and option exercise: September 15, 2026 +2 more

5 metrics

Shares to be sold under Rule 144 95,666 shares Maximum number of Travere Therapeutics common shares covered in the notice

Aggregate market value $6,293,866.14 Aggregate market value for the 95,666 shares as of September 15, 2026

Date of proposed sale and option exercise September 15, 2026 Date listed for both the securities information and the stock option exercise

Security type Common stock Class of Travere Therapeutics securities covered by the Form 144

Broker Morgan Stanley Smith Barney LLC Executive Financial Services Firm listed as handling the sale of the shares

Key Terms

Rule 144, Exercise of Stock Options, aggregate market value, Issuer

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 09/15/2026 | Exercise of Stock Options | Issuer"

aggregate market value financial

"Common ... | 95666 | 6293866.14 | 94261082 | 09/15/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Issuer regulatory

"Common | 09/15/2026 | Exercise of Stock Options | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Travere Therapeutics (TVTX)?

It discloses that Eric Dube filed a Rule 144 notice to sell up to 95,666 shares of Travere Therapeutics common stock following a cash exercise of stock options dated September 15, 2026.

How many TVTX shares are covered by Eric Dube’s planned Rule 144 sale?

The filing covers up to 95,666 shares of Travere Therapeutics common stock that may be sold under Rule 144 in connection with the reported transaction.

What is the aggregate market value of the Travere Therapeutics shares in this Form 144?

The notice lists an aggregate market value of $6,293,866.14 for the 95,666 shares of Travere Therapeutics common stock covered as of September 15, 2026.

How will the TVTX shares be acquired for sale under this Form 144?

The shares are tied to an exercise of stock options from the issuer, with the Form 144 stating that the options will be exercised for cash on September 15, 2026.

Which broker is listed for the potential sale of Travere Therapeutics (TVTX) shares?

The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, as the broker for the potential sale of the Travere Therapeutics common stock.

On which market are the Travere Therapeutics shares in this Form 144 listed?

The common stock referenced in the Form 144 is listed on the NASDAQ market, as indicated in the securities information section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:43 PM Accepted by SEC EDGAR 09/15/2026 - 04:42 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001763494
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS, INC.
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive, Suite 300 San Diego CALIFORNIA 92130
Phone	8889697879
Name of Person for Whose Account the Securities are To Be Sold	ERIC DUBE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	95666	6293866.14	94261082	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2026	Exercise of Stock Options	Issuer			95666	09/15/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Eric Dube
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)